← Leaderboards
Christine Alewine
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorClinical TrialsMalignant Neoplasm Of PancreasMesothelinMalignant NeoplasmsPharmaceutical PreparationsPancreatic Ductal AdenocarcinomaPre-Clinical ModelImproved OutcomeCollaborationsExtramural ActivitiesJournalsCombined Modality TherapyResearch PersonnelImmuneSafetyManuscriptsClinical ResearchPancreatic Cancer CellsMouse ModelImmunotoxinsEngineeringPreclinical StudyCell Killing
Grant awards (34)
First in Human Trials of ProAgio, a Cytotoxin$928,360
ZIA · FY2025 · CA · contact PI
Precision Therapy to Target Pancreatic Ductal Adenocarcinoma$568,383
ZIA · FY2025 · CA · contact PI
Rare Exocrine Tumors of the Pancreas$378,923
ZIA · FY2025 · CA · contact PI
Clinical Support$18,946
ZIE · FY2025 · CA · contact PI
First in Human Trials of ProAgio, a Cytotoxin$776,238
ZIA · FY2024 · CA · contact PI
Precision Therapy to Target Pancreatic Ductal Adenocarcinoma$475,248
ZIA · FY2024 · CA · contact PI
Rare Exocrine Tumors of the Pancreas$316,831
ZIA · FY2024 · CA · contact PI
Clinical Support$15,841
ZIE · FY2024 · CA · contact PI
First in Human Trials of ProAgio, a Cytotoxin$700,025
ZIA · FY2023 · CA · contact PI
Precision Therapy to Target Pancreatic Ductal Adenocarcinoma$682,524
ZIA · FY2023 · CA · contact PI
Rare Exocrine Tumors of the Pancreas$350,012
ZIA · FY2023 · CA · contact PI
Clinical Support$17,501
ZIE · FY2023 · CA · contact PI
First in Human Trials of ProAgio, a Cytotoxin$520,441
ZIA · FY2022 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$507,430
ZIA · FY2022 · CA · contact PI
Rare Exocrine Tumors of the Pancreas$260,221
ZIA · FY2022 · CA · contact PI
Clinical Support$13,011
ZIE · FY2022 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$863,617
ZIA · FY2021 · CA · contact PI
First in Human Trials of ProAgio, a Cytotoxin$345,447
ZIA · FY2021 · CA · contact PI
Clinical Support$12,337
ZIE · FY2021 · CA · contact PI
Rare Exocrine Tumors of the Pancreas$12,337
ZIA · FY2021 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$1,004,043
ZIA · FY2020 · CA · contact PI
First in Human Trials of ProAgio, a Cytotoxin$238,460
ZIA · FY2020 · CA · contact PI
Clinical Support$12,550
ZIE · FY2020 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$799,976
ZIA · FY2019 · CA · contact PI
First in Human Trials of ProAgio, a Cytotoxin$189,995
ZIA · FY2019 · CA · contact PI
Clinical Support$9,999
ZIE · FY2019 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$986,847
ZIA · FY2018 · CA · contact PI
Clinical Support$9,968
ZIE · FY2018 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$924,682
ZIA · FY2017 · CA · contact PI
Clinical Support$48,667
ZIE · FY2017 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$638,124
ZIA · FY2016 · CA · contact PI
Clinical Support$33,585
ZIE · FY2016 · CA · contact PI
Mesothelin-targeted immunotoxins in Pancreatic Cancer$476,998
ZIA · FY2015 · CA · contact PI
Clinical Support$25,106
ZIE · FY2015 · CA · contact PI